Vesicular stomatitis virus (VSV), an enveloped, negative-strand RNA virus, belongs to the Vesiculovirus genus of the Rhabdoviridae family. VSV has the ability to infect and kill cancer cells while sparing normal cells. VSV is a rapidly replicating, potently immunogenic virus which is amenable to engineering and has been deployed as a platform to develop prophylactic and therapeutic vaccines to prevent and/or treat infectious disease and oncolytic viruses for the treatment of cancer. Recombinant attenuated VSV vectors have been shown to replicate selectively in and kill cancer cells and are not pathogenic in humans. Tumor selectivity is due largely to cancer-specific defects in innate immune response pathways preventing malignant cells from mounting an effective antiviral response rendering them permissive to virus replication and killing. VSV is a particularly promising vector for development as an oncolytic therapy due to the lack of preexisting immunity to VSV in the general human population, allowing the development of agents that can potentially be administered systemically for the treatment of disseminated and metastatic cancers.
Creative Biogene has developed an all-sided QVirus™ platform, with this advanced platform, we offer customized, standardized and high-quality oncolytic vesicular stomatitis virus services for clients globally. By virtue of QVirus™, we are able to design, engineering and generate the most efficacious oncolytic vesicular stomatitis viral products.
